Xponance Inc. Purchases 277 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Xponance Inc. increased its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 11.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 2,659 shares of the company’s stock after buying an additional 277 shares during the period. Xponance Inc.’s holdings in Axsome Therapeutics were worth $225,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Assetmark Inc. acquired a new stake in shares of Axsome Therapeutics in the fourth quarter valued at about $52,000. R Squared Ltd acquired a new stake in Axsome Therapeutics in the 4th quarter valued at approximately $64,000. KBC Group NV grew its holdings in Axsome Therapeutics by 40.5% in the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after buying an additional 385 shares during the last quarter. Corient Private Wealth LLC bought a new position in Axsome Therapeutics in the 4th quarter worth approximately $239,000. Finally, Flower City Capital bought a new stake in shares of Axsome Therapeutics in the fourth quarter valued at approximately $254,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Stock Performance

Axsome Therapeutics stock opened at $118.53 on Friday. The firm has a market capitalization of $5.78 billion, a P/E ratio of -19.79 and a beta of 1.00. The stock has a fifty day moving average price of $119.67 and a two-hundred day moving average price of $101.09. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $139.13. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. The business had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. As a group, analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analyst Ratings Changes

AXSM has been the topic of a number of research reports. Mizuho boosted their target price on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the stock an “outperform” rating in a research report on Thursday. William Blair reaffirmed an “outperform” rating on shares of Axsome Therapeutics in a research report on Tuesday, February 18th. Robert W. Baird lifted their target price on Axsome Therapeutics from $132.00 to $160.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $153.00 price target on shares of Axsome Therapeutics in a report on Wednesday, February 19th. Finally, Truist Financial lifted their price objective on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $167.64.

Insider Transactions at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This represents a 6.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 22.40% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.